60 related articles for article (PubMed ID: 21165704)
21. Benefits and pitfalls of cardiovascular medication in seniors.
Kubesova HM; Weber P; Meluzinova H; Bielakova K; Matejovsky J
Wien Klin Wochenschr; 2013 Aug; 125(15-16):425-36. PubMed ID: 23846454
[TBL] [Abstract][Full Text] [Related]
22. Lipid lowering therapy in type 2 diabetes.
Föger B
Wien Med Wochenschr; 2011 Jun; 161(11-12):289-96. PubMed ID: 21769710
[TBL] [Abstract][Full Text] [Related]
23. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
24. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
25. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)].
Föger B; Patsch JR
Wien Klin Wochenschr; 2011 Jan; 123(1-2):21-7. PubMed ID: 21165704
[TBL] [Abstract][Full Text] [Related]
26. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
27. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
[TBL] [Abstract][Full Text] [Related]
28. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem.
Soubrier M; Zerkak D; Dougados M
J Rheumatol; 2006 Sep; 33(9):1766-9. PubMed ID: 16845709
[TBL] [Abstract][Full Text] [Related]
29. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].
Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY;
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.
Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
Lancet; 2009 Mar; 373(9667):929-40. PubMed ID: 19286092
[TBL] [Abstract][Full Text] [Related]
31. [Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)].
Roden M; Huber K;
Wien Klin Wochenschr; 2008; 120(17-18):558-65. PubMed ID: 18988009
[TBL] [Abstract][Full Text] [Related]
32. Use of recommended medications after myocardial infarction in Austria.
Winkelmayer WC; Bucsics AE; Schautzer A; Wieninger P; Pogantsch M;
Eur J Epidemiol; 2008; 23(2):153-62. PubMed ID: 18064529
[TBL] [Abstract][Full Text] [Related]
33. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
[TBL] [Abstract][Full Text] [Related]
35. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
